- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07622199
PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis
31 de agosto de 2026 actualizado por: RenJi Hospital
PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis: a Multicenter Randomized Controlled Study (The PROTECT Study)
Patients with iliofemoral vein thrombosis are prone to developing post-thrombotic syndrome (PTS).
The profunda femoris vein (PFV) is an important inflow of the iliofemoral vein.
Profunda femoris vein thrombosis clearance (PFV-TC) may improve the patency of iliofemoral vein and reduce the occurrence of PTS.
Descripción general del estudio
Estado
Reclutamiento
Condiciones
Descripción detallada
Acute lower extremity deep vein thrombosis (DVT) can lead to obstruction of veins, causing sudden lower limb swelling.
Patients may also develop post-thrombotic syndrome (PTS) manifesting as recurrent lower limb swelling, skin disorders, and even non-healing ulcers, which severely affects the patient's quality of life.
Among lower extremity DVT, thrombosis involving the iliofemoral veins is the most severe, with an incidence of PTS as high as 20%-50%.
Percutaneous mechanical thrombectomy (PMT) utilizes mechanical aspiration to rapidly remove thrombus, relieve venous obstruction, and restore luminal patency.
According to the results of a prospective clinical study, PMT can effectively improve the primary thrombus clearance rate and shorten hospital stay in patients with DVT.
Among 329 patients, 192 (58.5%) achieved complete thrombus removal using the AngioJet catheter.
PMT was once considered to be the first-line treatment option for DVT.
However, the results of the ATTRACT study, published in 2017 in New England Journal of Medicine, sparked considerable controversy regarding the use of PMT for DVT.
The ATTRACT study found that there was no significant difference in the incidence of PTS at two years after PMT compared with anticoagulation alone.
Although PMT can rapidly remove thrombus, is it unable to improve the long-term outcomes for patients with DVT?
According to previous studies, the primary patency rate at 12 months after PMT for acute iliofemoral venous thrombosis ranges from 77% to 85%, while the incidence of PTS at 24 months postoperatively is as high as 40%.
Residual thrombus is an important cause of thrombus recurrence, re-occlusion of the vein, and poor clinical outcomes.
Previous studies have primarily focused on thrombus clearance in the popliteal vein, superficial femoral vein, common femoral vein, and iliac vein, while neglecting the assessment and clearance of profunda femoris vein (PFV) thrombosis.
As the PFV is an important inflow of the iliofemoral vein, whether PFV-TC can improve the patency rate and clinical outcomes of endovascular treatment for acute iliofemoral DVT remains unclear.
In a preliminary study, the investigators analyzed and compared two cohorts: one receiving conventional endovascular treatment for acute iliofemoral venous thrombosis, and the other receiving conventional treatment combined with Profunda femoris vein thrombosis clearance (PFV-TC).
The results showed that the 24-month patency rate of the iliofemoral vein was 90% vs. 72%, and the incidence of PTS was 11% vs. 32% (P<0.05).
These findings were published in November 2025 in European Journal of Vascular and Endovascular Surgery.
This study has garnered widespread attention, and de Wolf MAF published an invited commentary on this study, acknowledging the value of this approach in the endovascular treatment of acute iliofemoral DVT.
Therefore, the investigators hypothesize that PFV-TC can improve inflow and reduce the incidence of PTS for iliofemoral DVT.
However, high-level evidence is still lacking.
The present study is a prospective, multicenter, randomized, open-label, evaluator-blinded, 1:1 parallel-controlled clinical trial investigating PFV-TC, aiming to obtain higher-level evidence to guide endovascular treatment of acute iliofemoral DVT.
Tipo de estudio
Intervencionista
Inscripción (Estimado)
140
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Qihong Ni
- Número de teléfono: +8615801900772
- Correo electrónico: niqihong1989@163.com
Ubicaciones de estudio
-
-
-
Shanghai, Porcelana
- Reclutamiento
- Renji Hospital
-
Contacto:
- Qihong Ni
- Número de teléfono: +8615801900772
- Correo electrónico: niqihong1989@163.com
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
No
Descripción
Inclusion Criteria:
- Age ≥ 18 years and ≤ 85 years;
- Diagnosed with acute iliofemoral DVT involving iliac vein, common femoral vein, and the proximal segment (orifice) of PFV (confirmed by preoperative ultrasound, CT venography, or pre-procedural venography);
- Time from symptom onset to endovascular treatment ≤ 14 days;
- Patient receives endovascular treatment with PMT;
- Patient provides written informed consent.
Exclusion Criteria:
- Presence of pre-existing PTS in the limb scheduled for treatment, or a history of symptomatic DVT in the same limb;
- Concurrent symptomatic acute DVT involving the iliac vein and/or common femoral vein in the contralateral limb;
- Known allergy to heparin, low-molecular-weight heparin, contrast media, or other relevant agents;
- Concomitant severe pulmonary embolism with hemodynamic compromise, such as hypoxia or hypotension;
- Intolerance to endovascular intervention due to concurrent acute systemic illness, severe dyspnea, or other contraindications;
- Concomitant severe renal insufficiency with creatinine clearance < 30 ml/min;
- Presence of active bleeding, severe hepatic insufficiency, bleeding diathesis, or other coagulation disorders;
- Concomitant severe anemia (hemoglobin < 8.0 mg/dL) or thrombocytopenia (platelet count < 80,000/mL);
- History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;
- Pregnancy;
- Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency) with an estimated life expectancy < 24 months;
- Participation in another clinical trial of a drug or medical device within the past 1 month that may interfere with the present study;
- Unwillingness to participate in this trial.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: PMT with PFV-TC group
PMT with PFV-TC group (experimental group)
|
PMT with PFV-TC group (experimental group): Based on the control group, access is obtained via the contralateral common femoral vein using a crossover technique, or via a popliteal-profunda communicating vessel approach to PFV.
The thrombus status of the PFV is assessed, and PMT is performed on the PFV thrombosis.
After thrombectomy, venography is performed to evaluate the patency of the PFV.
Successful PFV-TC is defined as the presence of continuous flow from the distal PFV to the CFV, including complete clearance (no residual thrombus) and partial clearance (continuous flow with residual thrombus).
Conversely, the absence of continuous flow is defined as failed PFV-TC.
|
|
Comparador activo: PMT without PFV-TC group
PMT without PFV-TC group (control group)
|
An appropriate puncture approach is selected, including the ipsilateral calf vein, ipsilateral popliteal vein, or ipsilateral femoral vein.
Under ultrasound guidance, a vascular sheath is inserted after puncture, and systemic heparinization is performed.
Using a guidewire and catheter, the guidewire is advanced antegradely into the inferior vena cava to establish a pathway.
After the pathway is established, PMT is performed using a mechanical thrombectomy device.
Acceptable thrombectomy devices include commercially available mechanical aspiration thrombectomy devices such as the AngioJet catheter (Boston Scientific, USA) and the Indigo catheter (Penumbra Inc, USA).
After thrombectomy, the outcome is evaluated by venography.
If iliac vein stenosis greater than 50% is detected, balloon dilation is performed using a balloon matched to the normal vessel diameter.
If residual stenosis remains greater than 50% after balloon dilation, stent implantation is performed.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of Post-Thrombotic Syndrome (PTS)
Periodo de tiempo: at 24 months
|
Assessed by the Villalta score.
The Villalta scale is the recommended tool for diagnosing and grading the severity of PTS.
It is a composite score based on 11 items (5 patient-reported symptoms and 6 clinician-assessed signs), each rated from 0 (absent) to 3 (severe), yielding a total score ranging from 0 to 33.
A score of 0-4 indicates no PTS, whereas a score of ≥5 or venous ulcer confirms the diagnosis of PTS.
Specifically, scores of 5-9 indicate mild PTS, 10-14 indicate moderate PTS, and a score of ≥15 or venous ulcer indicates severe PTS.
Higher scores reflect greater disease severity.
|
at 24 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of moderate-to-severe PTS
Periodo de tiempo: at 6, 12, and 24 months
|
Assessed by the Villalta score
|
at 6, 12, and 24 months
|
|
Patency rate of the ipsilateral iliofemoral vein
Periodo de tiempo: at 12 months and 24 months
|
Assessed by color Doppler ultrasound
|
at 12 months and 24 months
|
|
Recurrence rate of symptomatic Deep Vein Thrombosis (DVT)
Periodo de tiempo: at 24 months
|
Assessed by symptoms combined with ultrasound examination in the ipsilateral limb
|
at 24 months
|
|
Rate of re-intervention
Periodo de tiempo: at 24 months
|
Assessed by documentation of clinical reintervention
|
at 24 months
|
|
Incidence of PTS
Periodo de tiempo: at 6 and 12 months
|
Assessed by the Villalta score
|
at 6 and 12 months
|
|
Quality of life score
Periodo de tiempo: at 6, 12, and 24 months
|
Assessed by Venous Insufficiency Epidemiological and Economic Study Quality of Life questionnaire (VEINES-QOL).
The minimum value is 0 and the maximum value is 100.
Higher score means a better outcome.
|
at 6, 12, and 24 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of major bleeding
Periodo de tiempo: at 24 months
|
Defined by International Society on Thrombosis and Haemostasis (ISTH) criteria
|
at 24 months
|
|
Incidence of symptomatic Pulmonary Embolism (PE)
Periodo de tiempo: at 24 months
|
Assessed by symptoms combined with contrast-enhanced computed tomography examination
|
at 24 months
|
|
Incidence of symptomatic Venous Thromboembolism (VTE)
Periodo de tiempo: at 24 months
|
Assessed by symptoms combined with ultrasound and contrast-enhanced computed tomography examination
|
at 24 months
|
|
All-cause mortality
Periodo de tiempo: at 24 months
|
All-cause death
|
at 24 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
24 de junio de 2026
Finalización primaria (Estimado)
30 de junio de 2029
Finalización del estudio (Estimado)
31 de diciembre de 2029
Fechas de registro del estudio
Enviado por primera vez
26 de mayo de 2026
Primero enviado que cumplió con los criterios de control de calidad
26 de mayo de 2026
Publicado por primera vez (Actual)
3 de junio de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
2 de septiembre de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
31 de agosto de 2026
Última verificación
1 de agosto de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- The PROTECT Study
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .